The CRTC3 (CREB-regulated transcription coactivator 3) antibody is a tool used to study the CRTC3 protein, a member of the CRTC family (CRTC1. CRTC2. CRTC3) that regulates CREB (cAMP response element-binding protein)-mediated transcriptional activity. CRTC proteins act as coactivators, bridging CREB with the basal transcription machinery to modulate genes involved in stress responses, metabolism, and energy homeostasis. CRTC3. specifically, is highly expressed in adipose tissue, liver, and skeletal muscle, where it plays a critical role in metabolic regulation, including lipogenesis, gluconeogenesis, and insulin signaling. Dysregulation of CRTC3 has been linked to obesity, diabetes, and metabolic syndrome, making it a focus in metabolic disease research.
CRTC3 antibodies are designed to detect endogenous CRTC3 protein in applications such as Western blotting, immunohistochemistry, and immunofluorescence. They help investigate CRTC3’s subcellular localization, post-translational modifications (e.g., phosphorylation), and interactions with signaling pathways like cAMP, AMPK, or mTOR. CRTC3 is regulated by cellular energy status; under low-energy conditions, it translocates to the nucleus to activate target genes. Antibodies targeting specific domains or phosphorylation sites (e.g., Ser391) are essential for studying its functional states. Researchers also use these antibodies to explore CRTC3’s role in cancer, where its aberrant expression may promote tumor growth. Validation of CRTC3 antibodies includes testing in knockout models or siRNA-treated cells to confirm specificity, as cross-reactivity with other CRTC family members can occur. Proper controls are critical for accurate interpretation in experimental models.